The drugmaker entered into an asset purchase agreement with an affiliate of New Mountain Capital, an investment firm. Under the agreement, Aceto will sell its chemicals business for $338 million in cash, plus assumption of liabilities.
In addition, Aceto intends to enter into a stalking-horse agreement for its subsidiary, Rising Pharmaceuticals.
Aceto will continue operations as it works to sell its assets.
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
